Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715169 | 0.87 | L3MBTL1 (0.52) | L3MBTL1MAPTPOLBMAPK1EPHX2 | |
| SCHEMBL27913656 | 0.84 | L3MBTL1 (0.52) | L3MBTL1MAPTPOLBMAPK1EPHX2 | |
| SCHEMBL2713868 | 0.84 | L3MBTL1 (0.55) | L3MBTL1MAPTPOLBMAPK1EPHX2 | |
| SCHEMBL2714985 | 0.82 | L3MBTL1 (0.73) | L3MBTL1MAPTPOLBMAPK1EPHX2 | |
| SCHEMBL6634317 | 0.81 | KMT2A (0.50) | L3MBTL1MAPTCA12CA1CA2 | |
| SCHEMBL28012489 | 0.81 | L3MBTL1 (0.51) | L3MBTL1MAPTCXCR1CXCR2POLB | |
| SCHEMBL31670741 | 0.80 | MAPT (0.49) | L3MBTL1MAPTPDE4BCXCR1CXCR2 | |
| SCHEMBL796983 | 0.79 | EPHX2 (0.55) | L3MBTL1MAPTEPHX2 | |
| SCHEMBL2714784 | 0.78 | L3MBTL1 (0.48) | L3MBTL1MAPTPOLBMAPK1EPHX2 | |
| SCHEMBL1091973 | 0.76 | MAPT (0.55) | L3MBTL1MAPTPDE4BCXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6306880-B1 | HETEROCYCLIC ALCOHOL DERIVATIVES AS FUNGICIDES | SANKYO COMPANY, LIMITED (JP) | 2001-10-23 | — | — | US | disclosed |
| US-20010031778-A1 | Triazole antifungal agent | SANKYO COMPANY LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| US-20010031768-A1 | Triazole antifungal agent | SANKYO COMPANY LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| US-6300357-B1 | FOR THERAPY OF MYCOTIC DISEASE OF A HUMAN BEING AND AN ANIMAL | SANKYO COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-0841327-B1 | TRIAZOLE ANTIFUNGAL AGENT | SANKYO CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-5977152-A | Triazole antifungal agent | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0841327-A1 | TRIAZOLE ANTIFUNGAL AGENT | SANKYO COMPANY LIMITED (JP) | 1998-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031768-A1 | Triazole antifungal agent | ERG28, RIF1, NAT1 | L3MBTL1 2716/4885MAPT 3625/4885PDE4B 2666/4885 |
| US-20010031778-A1 | Triazole antifungal agent | ERG28, NAT1, RIF1 | L3MBTL1 2644/4885MAPT 2797/4885PDE4B 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.